REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.125
Bid: 3.00
Ask: 3.25
Change: -0.175 (-5.30%)
Spread: 0.25 (8.333%)
Open: 3.075
High: 3.38
Low: 3.10
Prev. Close: 3.30
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

3 Nov 2023 09:31

RNS Number : 3473S
Panmure Gordon (UK) Limited
03 November 2023

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader:

Panmure Gordon (UK) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Allergy Therapeutics plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Allergy Therapeutics plc

(d) Date dealing undertaken:

02 Nov 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

0.1p ordinary

Purchase

360,000

0.01306

0.01306

0.1p ordinary

Sales

83,244

0.01414

0.014

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing, or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

NONE

Date of disclosure:

03/11/2023

Contact name:

Freddie Wooding

Telephone number:

+44 (0)20 7886 2969

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FERZZMGMLFLGFZG
Date   Source Headline
23rd May 20227:00 amRNSAllergy Therapeutics at H.C. Wainwright Conference
25th Apr 20227:00 amRNSAllergy Therapeutics shares data at WAO-BSACI
7th Mar 20227:00 amRNSAllergy Therapeutics at Investor Meet Company
3rd Mar 20227:00 amRNSAllergy Therapeutics plc – Interim Results
1st Mar 20227:00 amRNSAllergy Therapeutics shares positive new data
24th Feb 20224:41 pmRNSSecond Price Monitoring Extn
24th Feb 20224:36 pmRNSPrice Monitoring Extension
24th Feb 20222:06 pmRNSSecond Price Monitoring Extn
24th Feb 20222:01 pmRNSPrice Monitoring Extension
2nd Feb 202211:05 amRNSSecures new revolving credit facility
1st Feb 20222:16 pmRNSTotal Voting Rights
26th Jan 20227:00 amRNSFDA clearance of IND application for VLP Peanut
24th Jan 20221:13 pmRNSHolding(s) in Company
13th Jan 20227:00 amRNSHalf Year Trading Update & Notice of Results
5th Jan 20228:47 amRNSTotal Voting Rights
25th Nov 20219:17 amRNSAllergy Therapeutics: Granting of Awards
23rd Nov 202112:54 pmRNSResult of AGM
11th Nov 20217:00 amRNSDirector Dealings
27th Oct 20217:00 amRNSCheryl MacDiarmid appointed to Board of Directors
25th Oct 20219:00 amRNSPrice Monitoring Extension
14th Oct 20219:24 amRNSHolding(s) in Company
7th Oct 20214:37 pmRNSAnnual Report and AGM Notification
23rd Sep 20217:00 amRNSPreliminary Results for Year ended 30 June 2021
16th Sep 20217:00 amRNSImmunoBON voted Most Innovative Product of 2021
13th Sep 20217:00 amRNSSecondary endpoints from VLP Peanut 001
9th Sep 20217:00 amRNSAllergy to Present at H.C. Wainwright Conference
7th Sep 20217:00 amRNSAllergy to host KOL webinar on VLP Peanut
3rd Aug 20217:00 amRNSSuccessful primary outcome of VLP Peanut 001
2nd Aug 202110:57 amRNSTotal Voting Rights
14th Jul 20217:00 amRNSTrading update for the year ended 30 June 2021
8th Jul 20217:00 amRNSAGY to present key scientific findings at EAACI
24th Jun 20217:00 amRNSTrading Update
1st Jun 20213:36 pmRNSTotal Voting Rights
10th May 20212:06 pmRNSSecond Price Monitoring Extn
10th May 20212:00 pmRNSPrice Monitoring Extension
6th May 20217:00 amRNSCompletion of treatment phase in G309 study
30th Apr 20215:47 pmRNSTotal Voting Rights
16th Apr 20217:00 amRNSAppointment of new Group auditors
31st Mar 20218:29 amRNSVesting of Awards under Long Term Incentive Plan
26th Mar 20214:39 pmRNSPledge of Shares
11th Mar 202112:13 pmRNSPledge of Shares
10th Mar 20214:40 pmRNSSecond Price Monitoring Extn
10th Mar 20214:35 pmRNSPrice Monitoring Extension
10th Mar 20212:05 pmRNSSecond Price Monitoring Extn
10th Mar 20212:00 pmRNSPrice Monitoring Extension
8th Mar 20217:00 amRNSAGY to Present at H.C. Wainwright Conference
3rd Mar 20217:00 amRNSInterim Results for six months ended 31 Dec 2020
15th Jan 20217:00 amRNSBlock Listing Return and Total Voting Rights
13th Jan 20217:00 amRNSHalf Year Trading Update 2021 & Notice of Results
8th Jan 20214:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.